ArticleJournal of neuro-oncology2009
Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas.
Article in Journal of neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Melatonin attenuates glandular cystitis via modulation of THBS1 and TLR4/p38 MAPK/STAT3 signaling.Scientific reports · 2025Article
- Co-Targeting MAP Kinase and Pi3K-Akt-mTOR Pathways in Meningioma: Preclinical Study of Alpelisib and Trametinib.Cancers · 2022Article
- mTOR Signaling and Potential Therapeutic Targeting in Meningioma.International journal of molecular sciences · 2022Review
- Identification of Meningioma Patients at High Risk of Tumor Recurrence Using MicroRNA Profiling.Neurosurgery · 2020Article
- Effect of miR-194-5p regulating STAT1/mTOR signaling pathway on the biological characteristics of ectopic endometrial cells from mice.American journal of translational research · 2020Article
- Synergistic effects and mechanisms of impressic acid or acankoreanogein in combination with docetaxel on prostate cancer.RSC advances · 2018Article
- STAT3 activation and risk of recurrence in meningiomas.Oncology letters · 2017Article
- mTOR activation is increased in pilocytic astrocytomas from older adults compared with children.Surgical neurology international · 2017Article
- Alpha-synuclein contributes to malignant progression of human meningioma via the Akt/mTOR pathway.Cancer cell international · 2016Article
- A six-microRNA set as prognostic indicators for bile duct cancer.International journal of clinical and experimental medicine · 2015Article
- Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.Virchows Archiv : an international journal of pathology · 2014Article
- Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.BMC complementary and alternative medicine · 2013Article
- Cerebrospinal fluid stimulates leptomeningeal and meningioma cell proliferation and activation of STAT3.Journal of neuro-oncology · 2012Article
- AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.Neuro-oncology · 2011Article
- Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.Targeted oncology · 2011Review
- Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas.Journal of neuro-oncology · 2011Article
- Frontier of epilepsy research - mTOR signaling pathway.Experimental & molecular medicine · 2011Review
- The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.Nature immunology · 2011Article
- Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism.Journal of neuro-oncology · 2011Article
- The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies.Surgical neurology international · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intracellular events promoting meningioma cell proliferation in high grade tumors are not established. In this study we compared 45 WHO grade I and 35 grade II or III meningiomas by Western blot or immunohistochemistry for phosphorylation/activation of the MEK-1-MAPK, PI3 K-Akt-mTOR-PRAS40 and STAT3 pathways. By Western blot, STAT3 activation was detected in 75% of grade I compared to 100% of grade II and III meningiomas. By immunohistochemistry p-STAT3 was detected in 28% of grade I compared to 65 or 66% of grade II and III meningiomas, respectively. Phosphorylated MEK-1 and p-MAPK were activated in nearly all grade I, II and III tumors. Phosphorylated Akt was also detected in the majority of meningiomas of each grade although downstream pathway component activation was less widespread. These findings suggest that there is increased STAT3 activation in WHO grade II and III meningiomas compared with grade I tumors. Moreover, each of the three major growth regulatory pathways is concomitantly activated in higher grade meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.